Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Huntington Bancshares: Tactical Long Into Q1 — Underwritten by Loan Growth and Stable Capital
A measured swing trade ahead of the next quarterly report — entry, stops and targets included.
Huntington (HBAN) looks fundamentally solid heading into the next quarterly report: sequential loan and asset growth, rising revenue and consistent ne...
HubSpot: Buy the 'Death of Software' Discount — Upgrade to Long (Trade Plan)
Q3 showed healthy revenue cadence, positive operating leverage and cash generation — market is pricing fear, not fundamentals.
HubSpot's Q3 FY25 results (11/05/2025) showed sequential revenue growth (QoQ ~6.4%), a return to positive operating income, and rising operating cash ...
Cisco: The Quiet Infrastructure Bet Backing the AI Buildout
A pragmatic long trade: buy the networking backbone of enterprise AI — entry, stops, targets and why the numbers support it
Cisco is little talked about in the AI conversation, but its networking, security and emerging silicon-photonics roadmap make it a direct beneficiary ...
Shopify: Expect choppier trading near-term — accumulate on dips for a multi-year winner
Short-term noise, long-term compounding; tactical entries, stops and targets for a disciplined approach
Shopify remains a structural winner in merchant commerce, but Q1–Q3 fiscal 2025 earnings and a strong 12-month price run show earnings volatility an...
Meta: AI Narrative Is Back — Tactical Long with Defined Stops and Targets
High cash flow, heavy AI investment and a beaten-down stock create an asymmetric swing trade setup
Meta (META) is trading off recent highs but still generates massive free cash flow and is aggressively deploying capital into AI and shareholder retur...
Aquestive (AQST) - Anaphylm Likely Fixable; a Tactical Long with Defined Risk
Regulatory deficiency is a headline, not a death knell - use size-limited exposure and clear stops while the company addresses FDA items
Aquestive’s Anaphylm NDA hit a regulatory snag (01/09/2026), but the company has the cash runway, patents and non-advisory history to warrant a tact...
Deutsche Bank: Rerating Is Done - Now Buy Proof Of Execution, Not Hype
A tactical long with defined entry, stop and targets that bets on execution - capital returns, trading momentum and stabilization across businesses.
DB has rerated sharply over the past year; the trade here is to buy into execution signals (dividends, trading gains, and cleaner balance sheet) with ...
QSR Swing Trade: Franchise Cash Flow + Unit Growth Backing a High-Quality, Under-the-Radar Upside
Restaurant Brands is posting accelerating sales and operating income while returning cash — set up a tactical long with defined stops and targets.
Restaurant Brands International (QSR) has quietly accelerated revenue and operating income over the last three quarters while producing strong operati...
Buy On Holding (ONON) — Tactical Long Into Momentum and Volatility Compression
A measured swing trade: buy the resilience, respect the volatility
On Holding (ONON) looks set for another leg higher after a healthy consolidation. The stock trades around $48.90 as of 01/12/2026, near intraday VWAP,...
loanDepot (LDI) — Buy the Operational Turnaround; Trade Plan for a Rebound
Improving cash flow and narrowing losses + favorable housing tailwinds make LDI an actionable long with defined entries and stops.
loanDepot has moved from acute cash-flow volatility to consecutive quarters of positive operating cash flow and sharply narrower operating losses. Rev...
Coca‑Cola FEMSA (KOF) - Buy for Yield and Optionality; Venezuela Upside Is a Bonus, Not the Driver
High-quality bottler, steady dividend, trading near 52-week highs but still offers a 3.9%-4.0% yield and event-driven upside.
Coca‑Cola FEMSA (KOF) is a large, cash-generative Coca‑Cola bottler with concentrated exposure to Mexico and Brazil (~80% of volumes/sales). At $9...
Gilead: Buy the Breakout — Income, Cash Flow and Oncology Upside Backing a Higher-High Trade
High cash generation, improving margins and late-stage clinical wins make GILD a tactical long with defined risk.
Gilead checks the boxes for a pragmatic, income-oriented long: strong operating cash flow (Q3 2025: $4.11B), widening profitability (Q3 2025 operating...